Dr. Meyer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2231 6th Street Southeast
4-165 CCRB
Minneapolis, MN 55455
Education & Training
- University of Vermont Medical CenterFellowship, Cardiovascular Disease, 2002 - 2006
- University of Vermont Medical CenterResidency, Internal Medicine, 2000 - 2003
- Albert Ludwigs University Faculty of MedicineClass of 1992
- Univ Freiburg- Fac MedClass of 1992
Certifications & Licensure
- MN State Medical License 2019 - 2025
- VT State Medical License 2006 - 2020
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Personalized Pacing: A New Paradigm for Patients With Diastolic Dysfunction or Heart Failure With Preserved Ejection Fraction Start of enrollment: 2019 Jul 17
- Cilostazol for HFpEF Start of enrollment: 2021 Sep 01
Roles: Contact
Publications & Presentations
PubMed
- Physiological Pacing for the Prevention and Treatment of Heart Failure: a State-of-the-Art Review.Margaret Infeld, Jamie A Cyr, Damián Sánchez-Quintana, Christopher Madias, James E Udelson
Journal of Cardiac Failure. 2024-12-01 - Personalized Accelerated Physiologic Dual Rate Pacing for Cardiac Amyloidosis.Markus Meyer, Valmiki Maharaj, Sneha Nandy, Rebecca Cogswell, Jop H van Berlo
JACC. Case Reports. 2024-11-20 - Cilostazol in patients with heart failure and preserved ejection fraction-The CLIP-HFpEF trial.Norman Aiad, Jeanne du Fay de Lavallaz, Michael J Zhang, Thanat Chaikijurajai, Bo Ye
ESC Heart Failure. 2024-11-17
Press Mentions
- Accelerated Pacing a Possible Strategy for HFpEF?February 6th, 2023
- Positive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1January 9th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: